Hair and Nail Adverse Events During Treatment with Targeted Therapies for Metastatic Melanoma

    Emi Dika, Annalisa Patrizi, Simone Ribero, Píer Alessandro Fanti, Michela Starace, Barbara Melotti, Francesca Sperandi, Bianca Maria Piraccini
    TLDR Targeted therapies for advanced skin cancer often cause hair and nail problems, which need managing to avoid changing the treatment dose.
    The study reviewed hair and nail adverse events associated with targeted therapies for metastatic melanoma, specifically focusing on drugs like vemurafenib, dabrafenib, and trametinib. These therapies, while effective in improving overall and progression-free survival rates in patients with BRAF mutations, were found to cause significant dermatologic side effects. The adverse events included changes in hair texture, hair loss, and various nail disorders. The findings highlighted the need for dermatologic monitoring and management in patients undergoing these treatments to improve their quality of life.
    Discuss this study in the Community →

    Research cited in this study

    7 / 7 results

    Related Community Posts Join

    6 / 1000+ results

    Related Research

    1 / 1 results